Significantly Improving Survival Rate of Pancreatic Cancer Through Early Diagnosis
The Deadliest Cancer
Despite medical advances, current methods of diagnosis and prognosis are insufficient for several common cancers. For example, due to late diagnosis and few treatment options of pancreatic ductal adenocarcinoma (PDAC), only 12% of patients survive after 5 years. This makes PDAC one of the deadliest cancers, with more than 400,000 annual deaths worldwide.
With rising obesity and Type 2 diabetes, the number of deaths caused by PDAC will only grow and it will possibly overtake lung cancer as the leading cause of cancer-related deaths.
We aim to give patients with PDAC a better chance at life through early diagnosis, when treatment can make the biggest difference.
“Most pancreatic cancer patients die of their disease…If they (CARE-DNA) develop a sensitive method that can be used for screening for early detection this will be a tremendously good thing for the patients.“
— Leading PDAC expert, Prof. Julia Sidenius Johansen, MD, DMSc. Professor. Department of Oncology Herlev and Gentofte Hospital.